Situated in Sydney’s Macquarie Park and built to pharmaceutical specifications, Recce and its anti-infective formulations are produced in its wholly owned, automated manufacturing facility with existing output of 500 doses per hour at a 99.9% product yield.
We have established a patented, automated, economical manufacturing process for our synthetic compounds. We have invested in a purpose built, wholly owned manufacturing facility, produced to the highest pharmaceutical standards.
Furthermore, the manufacturing process is reproducible and has a CMC (Chemistry, Manufacturing, and Controls) data package, essential for clinical study materials.
Recce has demonstrated manufacturing quality and volume capabilities for RECCE® 327’s indicated first in-human clinical trials.